Aortic thrombosis in a patient with a late diagnosis of Behcet's disease

Detanico, Ana Bittencourt; Brandão, Marcelo Luiz Lima; Fernandes, Ly de Freitas; Camêlo, Carolina Parreira Ribeiro; Santos, Juliano Ricardo Santana dos

doi:10.1590/1677-5449.0065

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BD usually affects young people aged 20 to 40 years [10 ]. The male-to-female ratio is 3:1, [11] and young males have a higher risk and worse prognosis [12].…”

Section: Discussionmentioning

confidence: 99%

“…Treatment is variable and depends on disease severity and organ involvement. When traditional immunosuppressive agents are insufficient for severe and resistant disease, biologicals like tumor necrosis factorα (TNF-α) inhibitors are an important therapeutic option [10]. Ocular, vascular, neurological, and gastrointestinal involvements are associated with a poor prognosis [7,8].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Refractory Ocular Behçet’s Disease; Outcome of Low Dose Infliximab

Ferdous¹,

Islam

Rahman³

et al. 2019

Rheum Res

View full text Add to dashboard Cite

A 40-year-old woman had been suffering from many symptoms of Behçet's disease (BD) since her childhood without being diagnosed. She had recurrent mouth ulcers and, from the age of 21, vulva ulcers followed by loss of vision due to central retinitis and later also ankle arthritis. At the age of 31, uveitis due to BD was diagnosed. The fact that BD is often not recognized in Bangladesh explains the marked delay in her diagnosis. The initial central retinitis responded well to oral glucocorticoids, azathioprine, and cyclosporine, but in the course of time she became refractory to these agents. Considering her financial constraints, low dose Infliximab (3mg/kg) was used and resulted in a remarkable but temporal improvement. She went into remission by using a regimen of 5 mg/kg with increased interval time. In this article, the treatment options for ocular involvement in BD patients are summarized. Conclusions: In countries like Bangladesh, the diagnosis of Behçet's disease can be delayed. The early cooperation of dermatologists and eye surgeons with rheumatologists is necessary. Most cases of resistant ocular BD today can be successfully treated with anti-TNF agents. Promising results are published with other biologics for refractory and multi-resistant cases.

show abstract

“…BD usually affects young people aged 20 to 40 years [10 ]. The male-to-female ratio is 3:1, [11] and young males have a higher risk and worse prognosis [12].…”

Section: Discussionmentioning

confidence: 99%